Trials / Completed
CompletedNCT00732056
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Geron Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer (MBC)
Detailed description
GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GRN163L | 25% dose escalation infused over 2 hours weekly |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-09-01
- Completion
- 2012-03-01
- First posted
- 2008-08-11
- Last updated
- 2015-12-24
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00732056. Inclusion in this directory is not an endorsement.